Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicholas Badham"'
Autor:
Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kina
Externí odkaz:
https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
Autor:
Christopher J. Lord, Alan Ashworth, Stephen J. Pettitt, Nicholas C. Turner, Aditi Gulati, James Campbell, Nicholas Badham, Rumana Rafiq, Jessica Frankum, Helen N. Pemberton, Isaac Garcia-Murillas, Asha Konde, Malini Menon, Inger Brandsma, Rachel Brough, Chris T. Williamson, Amy Dréan
Figure S1: Characterisation of CAPAN1-B2S* Figure S2: Characterisation of SUM149-B1S* Figure S3: Sensitivity of ddPCR assay. Figure S4: Olaparib and talazoparib select for secondary mutant tumour cells. Figure S5: DLD1 tumour cells have a fitness adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c87fbc8e38f13dde6b24d9910847b29
https://doi.org/10.1158/1535-7163.22508823.v1
https://doi.org/10.1158/1535-7163.22508823.v1
Autor:
Christopher J. Lord, Alan Ashworth, Stephen J. Pettitt, Nicholas C. Turner, Aditi Gulati, James Campbell, Nicholas Badham, Rumana Rafiq, Jessica Frankum, Helen N. Pemberton, Isaac Garcia-Murillas, Asha Konde, Malini Menon, Inger Brandsma, Rachel Brough, Chris T. Williamson, Amy Dréan
ddPCR probe and primer design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761be8a75a4e995d41eba19da335de90
https://doi.org/10.1158/1535-7163.22508817.v1
https://doi.org/10.1158/1535-7163.22508817.v1
Autor:
Asha Konde, Malini Menon, Inger Brandsma, Helen Pemberton, James Campbell, Alan Ashworth, Chris T. Williamson, Rachel Brough, Amy Dréan, Christopher J. Lord, Nicholas Badham, Nicholas C. Turner, Rumana Rafiq, Isaac Garcia-Murillas, Aditi Gulati, Jessica Frankum, Stephen J. Pettitt
Publikováno v:
Molecular Cancer Therapeutics. 16:2022-2034
Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96ed45c1bff42180a75bb7f2c5d3af3b
https://doi.org/10.1158/1535-7163.mct-17-0098
https://doi.org/10.1158/1535-7163.mct-17-0098
Autor:
Amy, Dréan, Chris T, Williamson, Rachel, Brough, Inger, Brandsma, Malini, Menon, Asha, Konde, Isaac, Garcia-Murillas, Helen N, Pemberton, Jessica, Frankum, Rumana, Rafiq, Nicholas, Badham, James, Campbell, Aditi, Gulati, Nicholas C, Turner, Stephen J, Pettitt, Alan, Ashworth, Christopher J, Lord
Publikováno v:
Molecular cancer therapeutics. 16(9)
Although PARP inhibitors target BRCA1 or BRCA2 mutant tumour cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d07d36fc09d0e4f3ec6c22a3f62fbf2d
https://pubmed.ncbi.nlm.nih.gov/28619759
https://pubmed.ncbi.nlm.nih.gov/28619759